These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17214585)

  • 41. Cytokines in the immunopathology of systemic sclerosis.
    Raja J; Denton CP
    Semin Immunopathol; 2015 Sep; 37(5):543-57. PubMed ID: 26152640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
    Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Scar wars: is TGFbeta the phantom menace in scleroderma?
    Leask A
    Arthritis Res Ther; 2006; 8(4):213. PubMed ID: 16774692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic sclerosis: from pathogenesis to targeted therapy.
    Denton CP
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis.
    Wei J; Bhattacharyya S; Varga J
    Curr Opin Rheumatol; 2010 Nov; 22(6):671-6. PubMed ID: 20693905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Criteria to select molecular targets for anti-fibrotic therapy.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v12-3. PubMed ID: 18784127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-fibrotic effects of Astragaloside IV in systemic sclerosis.
    Qi Q; Mao Y; Yi J; Li D; Zhu K; Cha X
    Cell Physiol Biochem; 2014; 34(6):2105-16. PubMed ID: 25562158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
    Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?
    Busquets J; Del Galdo F; Kissin EY; Jimenez SA
    Rheumatology (Oxford); 2010 Jun; 49(6):1069-75. PubMed ID: 20202926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches.
    Yin H; Li R; Lu L; Yan Q
    Curr Rheumatol Rep; 2020 Sep; 22(11):77. PubMed ID: 32959073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential roles of interleukin-17A in the development of skin fibrosis in mice.
    Okamoto Y; Hasegawa M; Matsushita T; Hamaguchi Y; Huu DL; Iwakura Y; Fujimoto M; Takehara K
    Arthritis Rheum; 2012 Nov; 64(11):3726-35. PubMed ID: 22833167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ubiquitination in Scleroderma Fibrosis and Its Treatment.
    Long Y; Chen W; Du Q; Zuo X; Zhu H
    Front Immunol; 2018; 9():2383. PubMed ID: 30386338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative stress in the pathogenesis of systemic scleroderma: An overview.
    Vona R; Giovannetti A; Gambardella L; Malorni W; Pietraforte D; Straface E
    J Cell Mol Med; 2018 Jul; 22(7):3308-3314. PubMed ID: 29664231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.
    Aden N; Nuttall A; Shiwen X; de Winter P; Leask A; Black CM; Denton CP; Abraham DJ; Stratton RJ
    J Invest Dermatol; 2010 Sep; 130(9):2191-200. PubMed ID: 20445556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel investigational agents for the treatment of scleroderma.
    McMahan ZH; Wigley FM
    Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.
    Bhattacharyya S; Wang W; Tamaki Z; Shi B; Yeldandi A; Tsukimi Y; Yamasaki M; Varga J
    Front Immunol; 2018; 9():2434. PubMed ID: 30405628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.
    Dimitroulas T; Daoussis D; Garyfallos A; Sfikakis PP; Kitas GD
    Curr Med Chem; 2015; 22(16):1943-55. PubMed ID: 25850767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.